Blog
RSS FeedPosted by Michael Wonder on 13 Dec 2023
Velmanase alfa for the treatment of patients with alfa mannosidosis
13 December 2023 - NICE has published final evidence-based recommendations on the use of velmanase alfa (Lamzede) for treatment of ...
Posted by Michael Wonder on 13 Dec 2023
Pembrolizumab and chemotherapy with or without bevacizumab for patients with persistent, recurrent or metastatic cervical cancer
13 December 2023 - NICE has published final evidence-based recommendations on the use of pembrolizumab (Keytruda) and chemotherapy with or ...
Posted by Michael Wonder on 12 Dec 2023
Efgartigimod for the treatment of patients with generalised myasthenia gravis (draft guidance 2)
12 December 2023 - NICE has published further draft guidance on the use of efgartigimod for the treatment of patients ...
Posted by Michael Wonder on 11 Dec 2023
SMC - December 2023 decisions
11 December 2023 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
Posted by Michael Wonder on 07 Dec 2023
Updates to the HTA Policy and Methods Review Reference Committee (8 December 2023)
8 December 2023 - The agenda for the HTA Review Reference Committee meeting (meeting 29) held on 1 December 2023 is ...
Posted by Michael Wonder on 07 Dec 2023
Dupilumab for the treatment of patients with eosinophilic oesophagitis
7 December 2023 - NICE is unable to make a recommendation on the use of dupilumab (Dupixent) for the treatment of ...
Posted by Michael Wonder on 06 Dec 2023
PHARMAC’s new equity policy
6 December 2023 - PHARMAC is drafting its first Equity Policy which outlines the mahi PHARMAC does, can do, or needs ...
Posted by Michael Wonder on 06 Dec 2023
Secukinumab for the treatment of patients with moderate to severe hidradenitis suppurativa (final guidance)
6 December 2023 - NICE has published final evidence-based recommendations on the use of secukinumab (Cosentyx) for the treatment of ...
Posted by Michael Wonder on 06 Dec 2023
Being more strategic and coordinated when we collaborate
6 December 2023 - Like other health entities, PHARMAC is busy working on strategies to meet the requirements of the ...
Posted by Michael Wonder on 04 Dec 2023
Vosoritide in achondroplasia: indication of an additional clinical benefit for children aged two and over
1 December 2023 - Two small RCTs with children of different ages together make it possible to make one statement: the ...
Posted by Michael Wonder on 04 Dec 2023
PHARMAC publishes minutes from August 2023 PTAC meeting
3 December 2023 - The meeting was held on 17-18 August 2023. After looking at the agenda, one asks why did ...
Posted by Michael Wonder on 03 Dec 2023
Agenda for the December 2023 PBAC intracycle meeting
1 December 2023 - The agenda for the December 2023 PBAC intracycle meeting is now available. ...
Posted by Michael Wonder on 02 Dec 2023
Steve Maharey quits as chair of PHARMAC, ACC
1 December 2023 - Both the Health Minister Dr Shane Reti and Minister for ACC Matt Doocey announced today they ...
Posted by Michael Wonder on 02 Dec 2023
PHARMAC making progress on action plan to enhance organisational culture
1 December 2023 - PHARMAC is making progress to enhance the organisational culture with all immediate tasks in the action ...
Posted by Michael Wonder on 02 Dec 2023
Updates to the HTA Policy and Methods Review Reference Committee (1 December 2023)
1 December 2023 - To ensure that the Reference Committee has sufficient time to consider the extensive and valuable input ...